Table 1.
Baseline characteristics at admission stratified by diabetes status
| All, n=4111 | Known DM, n=835 (20.3%) | Not known DM, n=3276 (79.7%) | p Value* | Missing value (%) | |
|---|---|---|---|---|---|
| Demography | |||||
| Age (years) | 66.4 (13.3) | 68.6 (11.8) | 65.8 (13.6) | <0.005 | 0.0 |
| Women (%) | 1224 (29.8) | 276 (33.1) | 948 (28.9) | 0.022 | 0.0 |
| Ethnicity (%) | |||||
| White European | 3381 (82.2%) | 545 (16.1) | 2836 (86.6) | <0.005 | 0.0 |
| South Asian | 730 (17.8%) | 290 (39.7%) | 440 (60.3%) | 0.0 | |
| Medical history (%) | |||||
| Hypertension | 2048 (50.3) | 584 (70.0) | 1464 (45.0) | <0.005 | 1.0 |
| Current/ex-smoker | 1366 (35.7) | 282 (36.8) | 1084 (35.5) | 0.527 | 7.1 |
| Coronary heart disease† | 491 (12.1) | 149 (17.9) | 342 (10.6) | <0.005 | 0.9 |
| CVA | 254 (6.3) | 86 (10.3) | 168 (5.2) | <0.005 | 1.2 |
| PVD | 154 (3.8) | 42 (5.0) | 112 (3.5) | 0.041 | 1.2 |
| Heart failure | 190 (4.7) | 76 (9.1) | 114 (3.5) | <0.005 | 1.2 |
| Type of infarction (%) | |||||
| STEMI | 2397 (58.3) | 417 (49.9) | 1980 (60.4) | <0.005 | 0.0 |
| NSTEMI | 1714 (41.7) | 418 (50.1) | 1296 (39.6) | ||
| Physical examination | |||||
| Heart rate (beats/min) | 81.1 (24.3) | 85.5 (25.3) | 80.0 (24.0) | <0.005 | 1.5 |
| SBP (mm Hg) | 136.5 (28.4) | 137.7 (30.7) | 136.2 (27.8) | 0.202 | 1.0 |
| Biochemical data | |||||
| Peak CK (IU/l, normal range <200) | 1113.5 (1810.4) | 939.9 (1279.3) | 1156.4 (1917) | <0.005 | 7.6 |
| Creatinine (µmol/l) | 116.4 (63.8) | 128.8 (76.1) | 113.1 (59.8) | <0.005 | 16.8 |
| eGFR (ml/min) | 63.0 (22.2) | 57.7 (23.6) | 64.4 (21.7) | <0.005 | 16.6 |
| Total cholesterol (mmol/l) | 5.1 (1.3) | 4.4 (1.2) | 5.2 (1.3) | <0.005 | 16.6 |
| Haemoglobin (g/l) | 13.7 (1.9) | 13.0 (1.9) | 13.9 (1.8) | <0.005 | 66.6 |
| Plasma glucose (mmol/l) | 8.8 (4.2) | 12.0 (5.5) | 7.9 (3.3) | <0.005 | 14.9 |
| Therapies (%) | |||||
| Prior to index admission | |||||
| Aspirin | 2671 (65.0) | 622 (74.5) | 2049 (62.5) | <0.005 | 0.0 |
| β-Blocker | 990 (25.6) | 265 (33.2) | 725 (23.6) | <0.005 | 6.0 |
| ACE inhibitor or ARB | 1097 (28.3) | 407 (51.0) | 690 (22.5) | <0.005 | 5.8 |
| Statins | 1083 (28.0) | 389 (48.7) | 694 (22.6) | <0.005 | 5.8 |
| In-hospital | |||||
| Reperfusion therapy‡ | 2414 (58.7) | 419 (50.2) | 1995 (60.9) | <0.005 | 0.0 |
| Loop diuretics | 1502 (37.4) | 436 (52.7) | 1066 (33.4) | <0.005 | 2.3 |
| At discharge | |||||
| Aspirin | 2701 (68.1) | 529 (65.3) | 2172 (68.8) | 0.057 | 3.5 |
| β-Blocker | 2513 (63.3) | 483 (59.6) | 2030 (64.3) | 0.013 | 3.5 |
| ACE inhibitor or ARB | 2493 (62.9) | 495 (61.0) | 1998 (63.4) | 0.222 | 3.6 |
| Statin | 2704 (67.7) | 537 (65.6) | 2167 (68.2) | 0.167 | 2.8 |
All values are mean (SD) or number (%).
*Known diabetes versus not-known diabetes.
†Any of angina/myocardial infarction/percutaneous intervention (PCI)/coronary artery bypass grafting (CABG).
‡Thrombolysis or coronary intervention (PCI or CABG) or both.
ARB, angiotensin receptor blocker; CK, creatinine kinase; CVA, cerebrovascular accidents; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate calculated using the MDRD formula; MDRD, modification of diet in renal disease; NSTEMI, non-ST elevation myocardial infarction; PVD, peripheral vascular disease; STEMI, ST elevation myocardial infarction; SBP, systolic blood pressure.